203 related articles for article (PubMed ID: 22452290)
21. Loss of keratin 19 favours the development of cholestatic liver disease through decreased ductular reaction.
Chen Y; Guldiken N; Spurny M; Mohammed HH; Haybaeck J; Pollheimer MJ; Fickert P; Gassler N; Jeon MK; Trautwein C; Strnad P
J Pathol; 2015 Nov; 237(3):343-54. PubMed ID: 26108453
[TBL] [Abstract][Full Text] [Related]
22. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis.
Moradpour D; Altorfer J; Flury R; Greminger P; Meyenberger C; Jost R; Schmid M
Hepatology; 1994 Dec; 20(6):1437-41. PubMed ID: 7982642
[TBL] [Abstract][Full Text] [Related]
23. Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis.
Joshi N; Ray JL; Kopec AK; Luyendyk JP
J Biochem Mol Toxicol; 2017 Jan; 31(1):1-7. PubMed ID: 27605088
[TBL] [Abstract][Full Text] [Related]
24. Experimental obliterative cholangitis. A model for the study of biliary atresia.
Schmeling DJ; Oldham KT; Guice KS; Kunkel RG; Johnson KJ
Ann Surg; 1991 Apr; 213(4):350-5. PubMed ID: 2009017
[TBL] [Abstract][Full Text] [Related]
25. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
Zhuang Y; Ortega-Ribera M; Thevkar Nagesh P; Joshi R; Huang H; Wang Y; Zivny A; Mehta J; Parikh SM; Szabo G
Hepatology; 2024 Apr; 79(4):752-767. PubMed ID: 37725754
[TBL] [Abstract][Full Text] [Related]
26. The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice.
Fickert P; Thueringer A; Moustafa T; Silbert D; Gumhold J; Tsybrovskyy O; Lebofsky M; Jaeschke H; Denk H; Trauner M
Lab Invest; 2010 Jun; 90(6):844-52. PubMed ID: 20368698
[TBL] [Abstract][Full Text] [Related]
27. Lamotrigine-induced vanishing bile duct syndrome in a child.
Bhayana H; Appasani S; Thapa BR; Das A; Singh K
J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):e147-8. PubMed ID: 22008955
[No Abstract] [Full Text] [Related]
28. Bile Acids and Biliary Fibrosis.
Aseem SO; Hylemon PB; Zhou H
Cells; 2023 Mar; 12(5):. PubMed ID: 36899928
[TBL] [Abstract][Full Text] [Related]
29. The role of biopsy in the evaluation of inflammatory diseases of the liver.
Orr W
Pathol Annu; 1973; 8():21-80. PubMed ID: 4598173
[No Abstract] [Full Text] [Related]
30. Effects of Melittin Treatment in Cholangitis and Biliary Fibrosis in a Model of Xenobiotic-Induced Cholestasis in Mice.
Kim KH; Sung HJ; Lee WR; An HJ; Kim JY; Pak SC; Han SM; Park KK
Toxins (Basel); 2015 Aug; 7(9):3372-87. PubMed ID: 26308055
[TBL] [Abstract][Full Text] [Related]
31. Atypical primary biliary cholangitis results in vanishing bile duct syndrome with cutaneous xanthomas: a case report.
Jia Y; Liu L; Deng B; Huang Y; Zhao J; Bai G
Diagn Pathol; 2022 Jul; 17(1):57. PubMed ID: 35787279
[TBL] [Abstract][Full Text] [Related]
32. Inflammation and biliary tract injury.
Lu BR; Mack CL
Curr Opin Gastroenterol; 2009 May; 25(3):260-4. PubMed ID: 19396964
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease.
Joshi N; Kopec AK; Ray JL; Luyendyk JP
Toxicology; 2016 Jul; 365():9-16. PubMed ID: 27475285
[TBL] [Abstract][Full Text] [Related]
34. The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment.
Cariello M; Gadaleta RM; Moschetta A
Curr Opin Gastroenterol; 2022 Mar; 38(2):136-143. PubMed ID: 35034082
[TBL] [Abstract][Full Text] [Related]
35. IL-21, not IL-17A, exacerbates murine primary biliary cholangitis.
Chan CW; Chen HW; Wang YW; Lin CI; Chuang YH
Clin Exp Immunol; 2024 Feb; 215(2):137-147. PubMed ID: 37708215
[TBL] [Abstract][Full Text] [Related]
36. The pathology of primary biliary cirrhosis and autoimmune cholangitis.
Ludwig J
Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):601-13. PubMed ID: 10976017
[TBL] [Abstract][Full Text] [Related]
37. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
Pollheimer MJ; Racedo S; Mikels-Vigdal A; Marshall D; Bowlus C; Lackner C; Madl T; Karlsen TH; Hov JR; Lyman SK; Adamkewicz J; Smith V; Moreau E; Zollner G; Eide TJ; Stojakovic T; Scharnagl H; Gruber HJ; Stauber RE; Trauner M; Fickert P
J Hepatol; 2018 Aug; 69(2):368-377. PubMed ID: 29709678
[TBL] [Abstract][Full Text] [Related]
38. Fibrinogen deficiency increases liver injury and early growth response-1 (Egr-1) expression in a model of chronic xenobiotic-induced cholestasis.
Luyendyk JP; Kassel KM; Allen K; Guo GL; Li G; Cantor GH; Copple BL
Am J Pathol; 2011 Mar; 178(3):1117-25. PubMed ID: 21356363
[TBL] [Abstract][Full Text] [Related]
39. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies.
Soroka CJ; Assis DN; Boyer JL
Methods Mol Biol; 2019; 1981():363-372. PubMed ID: 31016667
[TBL] [Abstract][Full Text] [Related]
40. Animal models of biliary tract injury.
Österreicher CH; Trauner M
Curr Opin Gastroenterol; 2012 May; 28(3):239-43. PubMed ID: 22450892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
